#adam19

[johniac]

SciTech Chronicles. . . . . . . .May 3rd, 2025

[moleculardepot]

Anti-ADAM19 Antibody

Anti-ADAM19 Antibody Catalog number: B2020560 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 100 ug/vial Molecular Weight or Concentration: N/A Supplied as: Lyophilized Applications: molecular tool for various biochemical applications Storage: -20°C Keywords: Anti-ADAM19 Antibody Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I…

[adam120709]

Я @adam_kzn со своей сестрой @evamariakazan #ева #евамария #eva #adam #adamkids_ #kzn19 #kznadam #kids #kidskzn #kidsadam_ #adam19 #eva19 #eva2019 #adam2019 (at Казанский федеральный университет - Электронное обучение) https://www.instagram.com/p/B2WpDJZnmb3/?igshid=19ovkab9bxbcs

[cancersfakianakis1]

Novel insights on m 6 A RNA methylation in tumorigenesis: a double-edged sword

Abstract

N6-methyladenosine (m6A), the most prevalent modification of mammalian RNA, has received increasing attention. Although m6A has been shown to be associated with biological activities, such as spermatogenesis modulation, cell spermatogenesis and pluripotency, Drosophila sex determination, and the control of T cell homeostasis and response to heat shock, little is known about its roles in cancer biology and cancer stem cells. Recent articles have noted that some genes have abnormal m6A expression after tumorigenesis, including genes ABS2, RARA, MYB, MYC, ADAM19 and FOX1. Abnormal changes in the m6A levels of these genes are closely related to tumour occurrence and development. In this review, we summarized the ‘dual edge weapon’ role of RNA methylation in the tumorigenesis. We discussed RNA methylation could lead to not only tumour progression but also tumour suppression. Moreover, we clarified that the abnormal changes in the m6A enrichment of specific loci contribute to tumour occurrence and development, thereby representing a novel anti-cancer strategy by restoration to balanced RNA methylation in tumour cells.

https://ift.tt/2LE4WYa

[moleculardepot]

Anti-ADAM19 Antibody

Anti-ADAM19 Antibody Catalog number: B2020560 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 100 ug/vial Molecular Weight or Concentration: N/A Supplied as: Lyophilized Applications: molecular tool for various biochemical applications Storage: -20°C Keywords: Anti-ADAM19 Antibody Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I…

[cancersfakianakis1]

Biallelic Dicer1 loss mediated by aP2-Cre drives angiosarcoma

Angiosarcoma is an aggressive vascular sarcoma with an extremely poor prognosis. Due to the relative rarity of this disease, its molecular drivers and optimal treatment strategies are obscure. DICER1 is an RNase III endoribonuclease central to microRNA biogenesis, and germline DICER1 mutations result in a cancer predisposition syndrome, associated with an increased risk of many tumor types. Here we show that biallelic Dicer1 deletion with aP2-Cre drives aggressive and metastatic angiosarcoma independent of other genetically engineered oncogenes or tumor suppressor loss. Angiosarcomas in aP2-Cre;Dicer1Flox/- mice histologically and genetically resemble human angiosarcoma. MicroRNA-23 target genes including the oncogenes Ccnd1 as well as Adam19, Plau, and Wsb1 that promote invasiveness and metastasis were enriched in mouse and human angiosarcoma. These studies illustrate that Dicer1 can function as a traditional loss-of-function tumor suppressor gene, and they provide a fully penetrant animal model for the study of angiosarcoma development and metastasis. http://ift.tt/2fbfVgr